|
|
|
Volumn 35, Issue 2, 2001, Pages 30-35
|
|
Grappling with the quality of life. Patients, FDA and drug companies struggle to link therapies with well-being.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALOSETRON;
ANTINEOPLASTIC AGENT;
CARBOLINE DERIVATIVE;
DRUG;
GASTROINTESTINAL AGENT;
ARTICLE;
DRUG APPROVAL;
FEMALE;
HUMAN;
IRRITABLE COLON;
MALE;
QUALITY OF LIFE;
ANTINEOPLASTIC AGENTS;
CARBOLINES;
COLONIC DISEASES, FUNCTIONAL;
DRUG APPROVAL;
FEMALE;
GASTROINTESTINAL AGENTS;
HUMANS;
MALE;
PHARMACEUTICAL PREPARATIONS;
QUALITY OF LIFE;
|
|
EID: 0035291276
PISSN: 03621332
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
